Table 1.
Cohort description.
| Pediatric PTCs n = 163 | ||
|---|---|---|
| Age | ||
| median, range | 16, 8–18 | |
| <15-year-old | 61 (37.4%) | |
| ≥15-year-old | 102 (62.6%) | |
| Sex | ||
| Female | 116 (71.2%) | |
| Male | 47 (28.8) | |
| Tumor size [cm] | ||
| mean (SD) | 2.3 (1.3) | |
| PTC variant | ||
| C-PTC | 99 (60.7%) | |
| FV-PTC | 34 (20.9%) | |
| SV-PTC | 9 (5.5%) | |
| TCV-PTC | 7 (4.3%) | |
| DSV-PTC | 4 (2.5%) | |
| HCV-PTC | 1 (0.6%) | |
| Metastasis without primary tumor * | 1 (0.6%) | |
| NIFTP * | 8 (4.9%) | |
| Tumor invasiveness | ||
| Totally encapsulated | 14 (9.1%) | |
| Encapsulated with tumor capsule invasion | 20 (13.0%) | |
| Infiltration of thyroid parenchyma | 120 (77.9%) | |
| Extrathyroidal extension | ||
| Minimal | 47 (30.5%) | |
| Gross | 1 (0.7%) | |
| Absent | 106 (68.8%) | |
| Multifocality | ||
| Present | 69 (44.8%) | |
| Absent | 85 (55.2%) | |
| Lymphovascular invasion | ||
| Present | 65 (42.2%) | |
| Absent | 89 (57.8%) | |
| Tumor stage | ||
| T1a | 20 (13.0%) | |
| T1b | 68 (44.1%) | |
| T2 | 45 (29.2%) | |
| T3a | 20 (13.0%) | |
| T4a | 1 (0.7%) | |
| Lymph node metastasis | ||
| N0 | 22 (14.3%) | |
| N1a | 35 (22.7%) | |
| N1b | 27 (17.5%) | |
| NA | 70 (45.5%) | |
Abbreviations: PTC, papillary thyroid carcinoma; C-PTC, classical papillary thyroid carcinoma; FV-PTC, follicular variant papillary thyroid carcinoma; SV-PTC, solid variant papillary thyroid carcinoma; TCV-PTC, tall cell variant papillary thyroid carcinoma; DSV-PTC, diffuse sclerosing variant papillary thyroid carcinoma; HCV-PTC, Hürthle cell variant papillary thyroid carcinoma; NIFTP, noninvasive follicular neoplasm with papillary-like nuclear features; NA, not available. * Excluded from further clinical-pathological characterization.